Sugi Predict

Sugi Predict / Targets / GRK3

GRK3

G protein-coupled receptor kinase 3 · P35626 · GRK3 on Sugi Atlas →

3,176 patent compounds predicted against GRK3, 2,271 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL5329771 SCHEMBL5329771 0.60 10/20
SCHEMBL5329784 SCHEMBL5329784 0.60 10/20
SCHEMBL5329635 SCHEMBL5329635 0.55 10/20
SCHEMBL5324946 SCHEMBL5324946 0.81 9/20
SCHEMBL5324952 SCHEMBL5324952 0.81 9/20
SCHEMBL5533102 SCHEMBL5533102 0.58 9/20
SCHEMBL5325448 SCHEMBL5325448 0.68 8/20
SCHEMBL5539705 SCHEMBL5539705 0.56 8/20
SCHEMBL5325627 SCHEMBL5325627 0.83 7/20
SCHEMBL5298786 SCHEMBL5298786 0.65 7/20
SCHEMBL5326560 SCHEMBL5326560 0.80 6/20
SCHEMBL5535877 SCHEMBL5535877 0.80 6/20
SCHEMBL5537424 SCHEMBL5537424 0.74 6/20
SCHEMBL5537734 SCHEMBL5537734 0.60 6/20
SCHEMBL2162900 SCHEMBL2162900 0.51 6/20
SCHEMBL4443422 SCHEMBL4443422 0.50 6/20
SCHEMBL7334908 SCHEMBL7334908 0.47 6/20
SCHEMBL3630014 SCHEMBL3630014 0.69 5/20
SCHEMBL3630016 SCHEMBL3630016 0.69 5/20
SCHEMBL5539470 SCHEMBL5539470 0.59 5/20

Clinical trials — most relevant to GRK3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress Syndrome PHASE2/PHASE3RECRUITING
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Dose Ranging Study of Carbidopa-levodopa PHASE2COMPLETED
Repurposing Chlorpromazine in the Treatment of Glioblastoma PHASE2UNKNOWN
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses PHASE1UNKNOWN
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study PHASE1UNKNOWN
Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer PHASE1COMPLETED
Measuring G Protein-coupled Receptor Kinase-2 (GRK2) in the Blood to Diagnose and Treat Patients With Heart Failure nanCOMPLETED
Genetic Predictors of Lithium Response in Bipolar Disorder nanCOMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Genetic Variants Associated With Adolescent Suicide Attempts nanCOMPLETED
Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein nanCOMPLETED
Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour nanUNKNOWN
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Multi-level Molecular Profiling of High Acute Stress: a Clinical Study nanUNKNOWN
Effect of Symbicort on GR Localisation in Asthma nanCOMPLETED
Brain Receptors in Sympathetic Nervous System Regulation nanCOMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
Metabotropic Receptors For Glutamate Type 3 In Parkinson's nanUNKNOWN
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism. nanNOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction nanCOMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
Acamprosate: Genes Associated With Response nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GRK3 binder may also engage these)

ProteinNameSimilarity
Q64682 — 1.000 Q64682 →
Q09639 — 1.000 Q09639 →
P26818 — 1.000 P26818 →
Q3UYH7 — 1.000 Q3UYH7 →
P26819 — 1.000 P26819 →
P32865 — 1.000 P32865 →
GRK2 Beta-adrenergic receptor kinase 1 1.000 landscape →
O97627 — 1.000 O97627 →
P26817 — 0.999 P26817 →
Q99MK8 — 0.998 Q99MK8 →
P21146 — 0.998 P21146 →
O12990 — 0.994 O12990 →
Q8VZD5 — 0.993 Q8VZD5 →
Q755C4 — 0.993 Q755C4 →
Q19266 — 0.993 Q19266 →
P52332 — 0.993 P52332 →
Q62074 — 0.992 Q62074 →
Q02956 — 0.992 Q02956 →
Q90XF2 — 0.992 Q90XF2 →
Q66JF3 — 0.992 Q66JF3 →
Q66I46 — 0.992 Q66I46 →
P51138 — 0.992 P51138 →
F1M7Y5 — 0.991 F1M7Y5 →
STK32A Serine/threonine-protein kinase 32A 0.991 landscape →
O19111 — 0.991 O19111 →
PRKCZ Protein kinase C zeta type 0.991 landscape →
A8WUG4 — 0.991 A8WUG4 →
P11730 — 0.991 P11730 →
A2CEA7 — 0.991 A2CEA7 →
Q5R4K9 — 0.991 Q5R4K9 →